Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 1.00 |
| ▸ | MTOR | P42345 | 20/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 1/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.66 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29561235 | 1.00 | PIK3CA (1.00) | PIK3CAMTORAURKBPIK3CDPIK3CB | |
| SCHEMBL29350061 | 1.00 | PIK3CA (1.00) | PIK3CAMTORAURKBPIK3CDPIK3CB | |
| SCHEMBL54844 | 0.90 | PIK3CA (0.82) | PIK3CAMTORAURKBPIK3CDPIK3CB | |
| SCHEMBL4992146 | 0.88 | PIK3CA (0.80) | PIK3CAMTORAURKBPIK3CG | |
| SCHEMBL4995368 | 0.88 | PIK3CA (0.80) | PIK3CAMTORAURKBPIK3CG | |
| SCHEMBL3985818 | 0.87 | PIK3CA (0.86) | PIK3CAMTORAURKBPIK3CG | |
| SCHEMBL20553524 | 0.85 | PIK3CA (0.74) | PIK3CAMTORAURKBPIK3CDPIK3CB | |
| SCHEMBL25678163 | 0.85 | PIK3CA (0.74) | PIK3CAMTORAURKBPIK3CDPIK3CB | |
| SCHEMBL3984934 | 0.85 | PIK3CA (0.84) | PIK3CAMTORAURKBPIK3CDPIK3CB | |
| SCHEMBL4990800 | 0.85 | PIK3CA (0.78) | PIK3CAMTORAURKBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | claimed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | claimed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | claimed |
| EP-4729121-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DERMAL DISORDERS | Drexel University (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3352755-B1 | TOPICAL COMPOSITION COMPRISING RAPAMYCIN FOR USE IN TREATING OR PREVENTING SEBORRHEIC KERATOSIS OR ACTINIC KERATOSIS | UNIV DREXEL (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-12378302-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4234031-A2 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230263781-A1 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE | PALVELLA THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20140206678-A1 | INHIBITORS OF MTOR KINASE AS ANTI -VIRAL AGENT | KADMON CORPORATION, LLC (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2014071419-A2 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20130158023-A1 | IDENTIFICATION OF GENE EXPRESSION AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158023-A1 | IDENTIFICATION OF GENE EXPRESSION AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013019927-A1 | IDENTIFICATION OF GENE EXPRESSION PROFILE AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-20 | — | — | US | disclosed |
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-20 | — | — | US | disclosed |
| WO-2011097333-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263781-A1 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE | MTOR, RICTOR, RPTOR | PIK3CA 14/4885MTOR 1/4885AURKB 2570/4885 |
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | STK11, STK16, STK10 | PIK3CA 85/4885MTOR 11/4885AURKB 547/4885 |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PIK3CA 2528/4885MTOR 4823/4885AURKB 1682/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | PIK3CA 2400/4885MTOR 4582/4885AURKB 1940/4885 |
| US-12378302-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | PIK3CA 2451/4885MTOR 4841/4885AURKB 1445/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PIK3CA 2528/4885MTOR 4823/4885AURKB 1682/4885 |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PDPK1 | PIK3CA 2/4885MTOR 1/4885AURKB 868/4885 |
| US-20130158023-A1 | IDENTIFICATION OF GENE EXPRESSION AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | STK16, STK10, STK11 | PIK3CA 195/4885MTOR 25/4885AURKB 691/4885 |
| US-20140206678-A1 | INHIBITORS OF MTOR KINASE AS ANTI -VIRAL AGENT | EIF2AK2, EEF2K, EIF2AK4 | PIK3CA 1130/4885MTOR 5/4885AURKB 1971/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PIK3CA 2451/4885MTOR 4841/4885AURKB 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.